Amundi Halozyme Therapeutics, Inc. Transaction History

Amundi

$253 Billion
Q2 2024

A detailed history of Amundi transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Amundi holds 120,427 shares of HALO stock, worth $6.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

120,427

Previous 149,889 19.66%

Holding current value

$6.85 Million

Previous $6.1 Million 3.41%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $1.11 Million - $1.54 Million	-29,462 Reduced 19.66%	120,427 $6.31 Million
Q1 2024 May 15, 2024	BUY	$33.68 - $41.95 $3.09 Million - $3.85 Million	91,781 Added 157.95%	149,889 $6.1 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $1.45 Million - $1.83 Million	43,508 Added 298.0%	58,108 $2.15 Million
Q3 2023 Nov 14, 2023	SELL	$36.46 - $44.03 $38,246 - $46,187	-1,049 Reduced 6.7%	14,600 $557,000
Q2 2023 Aug 14, 2023	SELL	$30.28 - $38.74 $7,176 - $9,181	-237 Reduced 1.49%	15,649 $564,000
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $32 - $55	-1 Reduced 0.01%	15,886 $606,000
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $56,364 - $83,632	1,407 Added 9.72%	15,887 $903,000
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $313,903 - $421,851	8,147 Added 128.64%	14,480 $603,000
Q2 2022 Aug 15, 2022	SELL	$37.35 - $48.3 $37,499 - $48,493	-1,004 Reduced 13.68%	6,333 $299,000
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $50,352 - $64,669	-1,575 Reduced 17.67%	7,337 $307,000
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $58,705 - $70,836	1,526 Added 20.66%	8,912 $363,000
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $286,872 - $378,975	7,386 New	7,386 $335,000

Others Institutions Holding HALO

# of Institutions

488

Shares Held

122M

Call Options Held

208K

Put Options Held

66.3K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.93B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account